צמיחת רווחי EPS רבעונית arcturusrx.com (ARCT)
Stable cash flow from licensing deals with industry behemoths supports the balance sheet of Arcturus Therapeutics (ARCT). The quarterly EPS change chart visualizes this financial stability, where the metric value stands at 46.80. LUNA technology and self-amplifying RNA enable the creation of effective vaccines with low dose volumes. However, fierce patent battles with large corporations create serious risks for the company's development.
%20%D7%A6%D7%9E%D7%99%D7%97%D7%AA%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%9E%D7%A9%D7%A0%D7%94%20%D7%9C%D7%A9%D7%A0%D7%94%20%D7%91-12%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_ARCT_-_Arcturus-Therapeutics_-_Year-over-year-earnings-per-share-growth-for-the-last-12-months "ARCT: צמיחת רווח נקי למניה משנה לשנה ב-12 החודשים האחרונים arcturusrx.com 04.07.2022 - 15.11.2026 | 👁️GURU.Markets👁️")
Arcturus Therapeutics (ARCT) - פילוחי מדדים ודוחות פיננסיים
Arcturus Therapeutics (ARCT) operates in the non-cyclical biotechnology sector, where asset value depends on patent successes. The net earnings per share trend here reflects the efficiency of capitalizing clinical developments. This indicator measures the quarterly percentage change in EPS, identifying points where growth drivers are exhausted. By analyzing the quarterly EPS growth rate, an investor can detect overvalued market expectations, allowing for a timely adjustment of the holding strategy.
